MEP0408A - Derivati hinociklicnog hinazolina kao inhibitori pde7 - Google Patents

Derivati hinociklicnog hinazolina kao inhibitori pde7

Info

Publication number
MEP0408A
MEP0408A MEP-04/08A MEP0408A MEP0408A ME P0408 A MEP0408 A ME P0408A ME P0408 A MEP0408 A ME P0408A ME P0408 A MEP0408 A ME P0408A
Authority
ME
Montenegro
Prior art keywords
spirocyclic
pde7 inhibitors
quinazoline derivatives
pain
compounds
Prior art date
Application number
MEP-04/08A
Other languages
Bosnian (bs)
English (en)
Inventor
David James Rawson
Nigel Alan Swain
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of MEP0408A publication Critical patent/MEP0408A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MEP-04/08A 2005-12-02 2006-11-23 Derivati hinociklicnog hinazolina kao inhibitori pde7 MEP0408A (xx)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74185405P 2005-12-02 2005-12-02
US79118606P 2006-04-10 2006-04-10
PCT/IB2006/003388 WO2007063391A2 (fr) 2005-12-02 2006-11-23 Derives spirocycliques

Publications (1)

Publication Number Publication Date
MEP0408A true MEP0408A (xx) 2010-02-10

Family

ID=37882213

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-04/08A MEP0408A (xx) 2005-12-02 2006-11-23 Derivati hinociklicnog hinazolina kao inhibitori pde7

Country Status (22)

Country Link
US (1) US7507742B2 (fr)
EP (1) EP1957467A2 (fr)
JP (1) JP2009517453A (fr)
KR (1) KR101009554B1 (fr)
AP (1) AP2008004470A0 (fr)
AR (1) AR058266A1 (fr)
AU (1) AU2006321349A1 (fr)
BR (1) BRPI0619126A2 (fr)
CA (1) CA2631535C (fr)
CR (1) CR10039A (fr)
EA (1) EA200801145A1 (fr)
EC (1) ECSP088484A (fr)
GT (1) GT200600494A (fr)
MA (1) MA30014B1 (fr)
ME (1) MEP0408A (fr)
NL (1) NL2000336C2 (fr)
NO (1) NO20082077L (fr)
PE (1) PE20071087A1 (fr)
RS (1) RS20080233A (fr)
TW (1) TW200732307A (fr)
UY (1) UY29979A1 (fr)
WO (1) WO2007063391A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
BRPI0609879A2 (pt) * 2005-04-28 2010-05-11 Pfizer Ltd derivados de aminoácidos
JP5580192B2 (ja) * 2007-03-27 2014-08-27 オメロス コーポレーション 運動障害の処置のためのｐｄｅ７インヒビターの使用
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
US20100216823A1 (en) * 2007-05-24 2010-08-26 Pfizer Inc. Spirocyclic Derivatives
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
TWI546537B (zh) * 2009-05-19 2016-08-21 維維亞生技公司 提供針對血液腫瘤之體外個人化藥物測試之方法
CN106038567A (zh) 2010-11-08 2016-10-26 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
WO2019014305A1 (fr) * 2017-07-12 2019-01-17 Dart Neuroscience, Llc Composés de benzoxazole et de benzofurane substitués utilisés en tant qu'inhibiteurs de pde7
US20260048059A1 (en) 2022-08-18 2026-02-19 Klaus Wirth Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intoleranc

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083772A1 (fr) 2000-04-28 2001-11-08 Merck Patent Gmbh Variant d'epissage de la phosphodiesterase de type 7 de camp (pde7a3)
AP1699A (en) 2001-03-21 2006-12-26 Warner Lambert Co New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
EP1400244A1 (fr) 2002-09-17 2004-03-24 Warner-Lambert Company LLC Nouveaux quinazolinones spirocondensés et leur utilisation comme inhibiteurs de la phosphodiesterase
CA2599662A1 (fr) * 2005-03-01 2006-09-08 Pfizer Limited Utilisation des inhibiteurs de pde7 pour le traitement de la douleur neuropathique
WO2006092692A1 (fr) * 2005-03-01 2006-09-08 Pfizer Limited Utilisation d'associations d’inhibiteurs de pde7 et de ligands alpha-2-delta pour le traitement de la douleur neuropathique

Also Published As

Publication number Publication date
US20070129388A1 (en) 2007-06-07
RS20080233A (sr) 2009-07-15
KR20080059338A (ko) 2008-06-26
EP1957467A2 (fr) 2008-08-20
AR058266A1 (es) 2008-01-30
BRPI0619126A2 (pt) 2011-09-13
WO2007063391A2 (fr) 2007-06-07
CA2631535A1 (fr) 2007-06-07
PE20071087A1 (es) 2007-12-29
CR10039A (es) 2008-07-10
TW200732307A (en) 2007-09-01
NO20082077L (no) 2008-06-04
NL2000336A1 (nl) 2007-06-05
GT200600494A (es) 2007-07-06
EA200801145A1 (ru) 2008-10-30
ECSP088484A (es) 2008-06-30
KR101009554B1 (ko) 2011-01-18
WO2007063391A3 (fr) 2007-09-13
CA2631535C (fr) 2010-07-27
MA30014B1 (fr) 2008-12-01
JP2009517453A (ja) 2009-04-30
AU2006321349A1 (en) 2007-06-07
US7507742B2 (en) 2009-03-24
NL2000336C2 (nl) 2007-08-07
AP2008004470A0 (en) 2008-06-30
UY29979A1 (es) 2007-06-29

Similar Documents

Publication Publication Date Title
NO20082077L (no) Spirosykliske quinazolinderivater som PDE7-inhibitorer
DE602004024375D1 (de) Carboxamidderivate
TW200615266A (en) Organic compounds
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
SE0202539D0 (sv) Compounds
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
WO2008005956A3 (fr) Inhibiteurs de pyrrolotriazine kinase
WO2010021934A3 (fr) Inhibiteurs azaindoles d’iap
SE0402925D0 (sv) Novel Compounds
EP2145878A3 (fr) Inhibiteurs de kinases Aurora
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
SE0302756D0 (sv) Novel Compounds
TW200639156A (en) New compounds
EP1453506A4 (fr) Agents toxiques de topoisomerase
SE0401763D0 (sv) Compounds
AU2002359150A8 (en) Therapeutic heterocycles
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
WO2004044174A3 (fr) Agents ciblant les topoisomerases
NO20063619L (no) Diarylmetylpiperazinderivater, fremstilling og anvendelse derav
MX2009005125A (es) Pirrolo[1,2-a]imidazoldiona efectiva en el tratamiento de neurotoxicidad periferica inducida por agentes quimioterapeuticos.